The effect of transnasal sphenopalatine ganglion blockade on pain, functional capacity, sleep, and depression in patients with fibromyalgia
Ağrı - The Journal of The Turkish Society of Algology · 2024
DOI: 10.14744/agri.2023.67790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ağrı - The Journal of The Turkish Society of Algology, 2024. Verfasst von Oktay Faysal Tertemiz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Algology, İzmir Health Sciences University, Tepecik Training and Research Hospital, İzmir, Türkiye. Hauptthemen laut MEDLINE: Fibromyalgia, Sphenopalatine Ganglion Block, Pain Measurement.
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Algology, İzmir Health Sciences University, Tepecik Training and Research Hospital, İzmir, Türkiye.
- Division of Pain Medicine-Algology, Department of Physical Medicine and Rehabilitation, Dokuz Eylül University Hospital, İzmir, Türkiye.
- Department of Neurology, Balıkesir University Faculty of Medicine, Balıkesir, Türkiye.
Zitieren
APA
Tertemiz, O. F., Özduran, E., & Tepe, N. (2024). The effect of transnasal sphenopalatine ganglion blockade on pain, functional capacity, sleep, and depression in patients with fibromyalgia. Ağrı - The Journal of The Turkish Society of Algology. https://doi.org/10.14744/agri.2023.67790
Vancouver
Tertemiz OF, Özduran E, Tepe N. The effect of transnasal sphenopalatine ganglion blockade on pain, functional capacity, sleep, and depression in patients with fibromyalgia. Ağrı - The Journal of The Turkish Society of Algology. 2024. doi:10.14744/agri.2023.67790
BibTeX
@article{Tertemiz2024,
author = {Tertemiz, Oktay Faysal and Özduran, Erkan and Tepe, Nermin},
title = {The effect of transnasal sphenopalatine ganglion blockade on pain, functional capacity, sleep, and depression in patients with fibromyalgia},
journal = {Ağrı - The Journal of The Turkish Society of Algology},
year = {2024},
doi = {10.14744/agri.2023.67790}
}
EUVIMED